DrugPatentWatch Database Preview
Alvogen Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for ALVOGEN, and when can generic versions of ALVOGEN drugs launch?
ALVOGEN has fifty-four approved drugs.
There is one US patent protecting ALVOGEN drugs.
There is one patent family member on ALVOGEN drugs in one country and one hundred and fifty-two supplementary protection certificates in fifteen countries.
Summary for Alvogen
| International Patents: | 1 |
| US Patents: | 1 |
| Tradenames: | 49 |
| Ingredients: | 46 |
| NDAs: | 54 |
| Patent Litigation for Alvogen: | See patent lawsuits for Alvogen |
| PTAB Cases with Alvogen as petitioner: | See PTAB cases with Alvogen as petitioner |
Drugs and US Patents for Alvogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alvogen Pine Brook | ESTRADIOL | estradiol | CREAM;VAGINAL | 209767-001 | Mar 5, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Alvogen Pine Brook | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | acetaminophen; hydrocodone bitartrate | TABLET;ORAL | 209958-003 | Oct 24, 2018 | DISCN | No | No | Start Trial | Start Trial | |||||
| Alvogen | MACROBID | nitrofurantoin; nitrofurantoin, macrocrystalline | CAPSULE;ORAL | 020064-001 | Dec 24, 1991 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alvogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alvogen | ZESTRIL | lisinopril | TABLET;ORAL | 019777-003 | May 19, 1988 | 4,374,829*PED | Start Trial |
| Alvogen | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-002 | Apr 21, 1993 | 5,264,446 | Start Trial |
| Alvogen | ZESTRIL | lisinopril | TABLET;ORAL | 019777-001 | May 19, 1988 | 4,374,829*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALVOGEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 450 mg | ➤ Subscribe | 2013-02-28 |
International Patents for Alvogen Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008038155 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alvogen Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2203431 | CR 2015 00014 | Denmark | Start Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| 1304992 | 2013C/060 | Belgium | Start Trial | PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506 |
| 0788511 | SPC/GB08/036 | United Kingdom | Start Trial | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
